What changed
$VRTX — BUY 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $3.0B | EPS $4.47 vs $4.31 🟢 | Margin 38.1%
💡 Consensus models CF growth modestly but assigns minimal value to pipeline beyond CF. Both suzetrigine (pain) and inaxaplin could contribute significant revenue by decade-end, which is not fully reflected in the current P/E multiple of ~26x.
📉 Reward/risk: 2.1:1
🏢 Business Quality: 9/10 - dominant monopoly in CF with high margins, strong IP, and a diversified pipeline in pain, kidney, and type 1 diabetes; excellent management and R&D track record.
📊 Valuation: fair to slightly undervalued — P/E 25.9x at 50th percentile of history, EV/EBITDA ~20x, FCF yield ~4.5%; DCF implies value >$550 if pipeline assets...
🔮 Catalyst: Phase 3 pivotal readout for inaxaplin (VX-147) in APOL1-mediated focal segmental glomerulosclerosis (FSGS)
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/VRTX0618